|

CUCART19 Clinical Trials

1 actively recruiting trial

Also known as: anti-CD19 CAR-T

Pipeline

Phase 2: 1

Top Sponsors

  • Chi Kong Li1

Indications

  • Leukemia, Lymphocytic1
  • Lymphoma, Nonhodgkin1
  • Cancer1

Other1 trial

Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.